Ardelyx Inc (ARDX) Stock
Fundamentals
Recent news

Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
ARDX

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
ARDX

Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
ARDX

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.02 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
ARDX

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
ARDX

Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
ARDX

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
ARDX

ARDX SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
ARDX SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
ARDX

Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action Lawsuit
Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action Lawsuit
ARDX

ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)
ARDX

New Strong Sell Stocks for August 7th
New Strong Sell Stocks for August 7th
ARDX

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates
Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates
ARDX

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
ARDX
About Ardelyx Inc
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael G. Raab | President, CEO & Director | 1965 |
| Ms. Sue Hohenleitner | Chief Financial Officer | 1971 |
| Dr. John Bishop Ph.D. | Chief Technical & Quality Officer | 1962 |
| Mr. Joseph Reilly | Senior VP of Finance & Principal Accounting Officer | 1974 |
| Ms. Lisa M. Caperelli | Senior Vice President of Investor Relations and Corporate Communications | — |
| Ms. Felecia W. Ettenberg | Chief Legal Officer | 1971 |
| Mr. James P. Brady | Chief Human Resources Officer | 1971 |
| Mr. Mike Kelliher | Chief Business Officer | 1977 |
| Dr. Rajani Dinavahi M.D. | Chief Medical Officer | 1976 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
5 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.1 | -6.9 | -5.8 | -10.6 | ||||||||
| 2022 | -29.7 | -8.3 | +46.6 | -23.4 | -21.4 | -4.8 | +18.6 | +41.8 | +21.4 | +11.9 | +9.6 | +62.9 |
| 2023 | +9.3 | -4.3 | +64.0 | -5.5 | -28.2 | -3.1 | +19.4 | +10.9 | -15.4 | -2.7 | +14.5 | +30.3 |
| 2024 | +44.3 | +0.3 | -21.8 | -13.6 | +3.8 | +7.1 | -26.7 | +12.4 | +22.4 | -14.3 | -6.9 | -8.5 |
| 2025 | +4.7 | +1.3 | -3.3 | +15.0 | -32.9 | +1.8 | +8.7 | +46.9 | -13.9 | +13.1 | -2.0 | +4.3 |
| 2026 | +25.0 | -15.9 | -7.4 | +3.6 | -12.2 | -11.0 | -4.1 | -24.1 | -9.0 |



